Vindesine in advanced renal cancer. A study of the EORTC Genito-urinary Tract Cancer Cooperative Group.
Vindesine at a dose of 3 mg/m2 i.v. once a week failed to produce responses in 24 adequately treated patients with measurable advanced renal carcinoma. Leukopenia and peripheral neurotoxicity were the most often observed side-effects. On the basis of the negative result, the application of vindesine in this disease is not recommended.